EUVIMEDEUVIMED entdecken
Crossref

Tezepelumab Reverses TSLP ‐Driven Immunometabolic Rewiring in Human cDC2s Underlying Pathogenic Th2 and Dysfunctional Treg Responses

Leticia Martín-Cruz iD, Andrés de la Rocha-Muñoz iD, Isabel María Peñalver-Fernández iD, Ángel Maldonado iD, Sofía Sirvent iD, Oscar Palomares iD

Allergy · 2026

DOI: 10.1111/all.70470 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergy, 2026. Verfasst von Leticia Martín-Cruz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University, Madrid, Spain. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Th2 Cells, Dendritic Cells, Cytokines. Die Arbeit nennt 50 Literaturangaben. Gefördert von: AstraZeneca Pharmaceuticals LP, Ministerio de Ciencia, Innovación y Universidades.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Thymic stromal lymphopoietin (TSLP) is a key epithelial alarmin involved in the initiation and maintenance of type 2 inflammatory airway diseases. Although tezepelumab, the first approved anti‐TSLP monoclonal antibody, has shown robust clinical efficacy in asthma and CRSwNP, the molecular mechanisms underlying its mode of action remain incompletely defined.

Objective

To determine whether TSLP induces a pathogenic immunometabolic program in human type 2 conventional dendritic cells (cDC2s) and whether tezepelumab can directly reverse this process.

Methods

Purified human circulating cDC2s from healthy non‐atopic donors were stimulated with TSLP in the presence or absence of tezepelumab. cDC2 phenotype, function, metabolism, and T‐cell polarization capacity were assessed. Pathogenic Th2 responses, Treg generation, suppressive function, and metabolic fitness were analyzed.

Results

TSLP induced a metabolic rewiring in human cDC2s characterized by increased glycolysis and mitochondrial oxidative phosphorylation. This metabolic hyperactivation was associated with the acquisition of a pro‐type 2 phenotype and required for the induction of pathogenic T‐cell responses. TSLP‐activated cDC2s generated pathogenic Th2 cells and FOXP3 + Tregs with impaired suppressive function and an altered metabolic profile. Tezepelumab effectively reversed TSLP‐induced metabolic and functional reprogramming in cDC2s, thereby limiting pathogenic Th2 polarization while restoring the functional and metabolic properties of induced Tregs.

Conclusions

We identify immunometabolic rewiring as a key mechanism of the TSLP–cDC2 axis and provide mechanistic insight into how tezepelumab reshapes pathogenic adaptive immune responses. These results support upstream epithelial alarmin blockade as a strategy to interfere with early disease‐driving immune programs in type 2 inflammatory airway diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

T-Lymphocytes, RegulatoryTh2 CellsDendritic CellsCytokinesAntibodies, MonoclonalHumansThymic Stromal LymphopoietinMetabolic ReprogrammingAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

TSLPasthmacDC2schronic rhinosinusitis with nasal polypsimmunometabolic rewiringpathogenic Th2 cellsregulatory T cellstezepelumab

Substanzen

Thymic Stromal LymphopoietinCytokinestezepelumabAntibodies, MonoclonalTSLP protein, humanAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University, Madrid, Spain.
  • Department of Biochemistry and Molecular Biology, School of Pharmacy, Complutense University, Madrid, Spain.
  • Autonomous University of Madrid, Madrid, Spain.

ORCID-Profile: Leticia Martín-Cruz, Andrés de la Rocha-Muñoz, Isabel María Peñalver-Fernández, Ángel Maldonado, Sofía Sirvent, Oscar Palomares

Förderung

  • AstraZeneca Pharmaceuticals LP
  • Ministerio de Ciencia, Innovación y Universidades

Zitieren

APA

Martín-Cruz, L., de la Rocha-Muñoz, A., Peñalver-Fernández, I. M., Maldonado, Á., Sirvent, S., & Palomares, O. (2026). Tezepelumab Reverses TSLP ‐Driven Immunometabolic Rewiring in Human cDC2s Underlying Pathogenic Th2 and Dysfunctional Treg Responses. Allergy. https://doi.org/10.1111/all.70470

Vancouver

Martín-Cruz L, de la Rocha-Muñoz A, Peñalver-Fernández IM, Maldonado Á, Sirvent S, Palomares O. Tezepelumab Reverses TSLP ‐Driven Immunometabolic Rewiring in Human cDC2s Underlying Pathogenic Th2 and Dysfunctional Treg Responses. Allergy. 2026. doi:10.1111/all.70470

BibTeX
@article{MartnCruz2026,
  author = {Martín-Cruz, Leticia and de la Rocha-Muñoz, Andrés and Peñalver-Fernández, Isabel María and Maldonado, Ángel and Sirvent, Sofía and Palomares, Oscar},
  title = {Tezepelumab Reverses TSLP ‐Driven Immunometabolic Rewiring in Human cDC2s Underlying Pathogenic Th2 and Dysfunctional Treg Responses},
  journal = {Allergy},
  year = {2026},
  doi = {10.1111/all.70470}
}
Kostenlos starten →